AIM ImmunoTech Inc (AMEX:AIM)’s traded shares stood at 0.46 million during the latest session, with the company’s beta value hitting -0.35. At the last check today, the stock’s price was $0.24, to imply a decrease of -0.33% or $0.0 in intraday trading. The AIM share’s 52-week high remains $0.62, putting it -158.33% down since that peak but still an impressive 12.5% since price per share fell to its 52-week low of $0.21. The company has a valuation of $14.15M, with an average of 0.5 million shares in intraday trading volume over the past 10 days and average of 290.27K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for AIM ImmunoTech Inc (AIM), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give AIM a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.1.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AIM ImmunoTech Inc (AMEX:AIM) trade information
After registering a -0.33% downside in the latest session, AIM ImmunoTech Inc (AIM) has traded red over the past five days. The 5-day price performance for the stock is -13.86%, and -27.15% over 30 days. With these gigs, the year-to-date price performance is -45.17%. Short interest in AIM ImmunoTech Inc (AMEX:AIM) saw shorts transact 0.5 million shares and set a 2.09 days time to cover.
AIM ImmunoTech Inc (AIM) estimates and forecasts
Looking at statistics comparing AIM ImmunoTech Inc share performance against respective industry, we note that the company has outperformed competitors. AIM ImmunoTech Inc (AIM) shares are -51.00% down over the last 6 months, with its year-to-date growth rate higher than industry average at 41.67% against 19.40%. Revenue is forecast to grow 37.50% this quarter before jumping 61.50% for the next one. The rating firms project that company’s revenue will shrink -10.90% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is 20k. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 70k.Earnings reports from the last fiscal year show that sales brought in 46k and 65k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -56.50% before jumping 7.70% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 42.86% for the past 5-year period. While 2024 is set for a 45.83% return in earnings, projections for the next 5 years are at 25.00% annually.
AIM Dividends
AIM ImmunoTech Inc has its next earnings report out on 2024-Nov-13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
AIM ImmunoTech Inc (AMEX:AIM)’s Major holders
AIM ImmunoTech Inc insiders hold 8.62% of total outstanding shares, with institutional holders owning 13.33% of the shares at 14.59% float percentage. In total, 13.33% institutions holds shares in the company, led by ARMISTICE CAPITAL, LLC. As of 2024-06-30, the company held over 4.08 million shares (or 8.2454% of shares), all amounting to roughly $1.52 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 1.99 million shares, or about 4.021% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $0.74 million.
